Edward Stelmakh is recorded as COO at OptimizeRx Corp (OPRX) since October 11, 2021 and CFO at OptimizeRx Corp (OPRX). OptimizeRx Corp reported in an 8-K filed August 12, 2026 that Edward Stelmakh was appointed Advisor, effective January 1, 2027. OptimizeRx Corp reported in an 8-K filed August 19, 2025 that Edward Stelmakh was appointed Chief Financial & Strategic Officer. The proxy statement of OptimizeRx Corp reports total compensation of $1,524,170 for Edward Stelmakh in fiscal 2025, including a base salary of $450,000. Disclosed compensation is on record for 5 fiscal years. Edward Stelmakh has spoken on 6 earnings calls across 1 company, most recently for OptimizeRx Corp on May 12, 2025. OptimizeRx Corp is classified in the Health Information Services industry within the Healthcare sector. Other leadership on record at OptimizeRx Corp includes Stephen Silvestro (CEO and Board Member), William Febbo (CEO and Board Member), William J. Febbo (CEO and Board Member) and 7 others.
“The Company hereby confirms your appointment (the “Appointment”) as an advisor (“Advisor”) to OptimizeRx Corporation (“OptimizeRx” or the “Company”) subject to the terms and conditions set forth below.”
OptimizeRx Corp Form 8-K, filed August 12, 2026
· Read the filing
“Ed Stelmakh has been appointed Chief Financial & Strategic Officer (CFSO), evolving from his previous responsibilities as the Company’s Chief Financial Officer & Chief Operations Officer to encompass corporate broader strategy alongside financial leadership.”
OptimizeRx Corp Form 8-K, filed August 19, 2025
· Read the filing
Edward Stelmakh on recent calls
“As with all our calls, the press release was issued this afternoon with the results of our first quarter ended March 31, 2025.”
“The press release was issued with financial results of our first quarter ended March 31, 2024. A copy is available for viewing and may be downloaded from the Investor Relations section of our website.”
“As noted previously, a transcript and a link to an audio recording of this conference call will be provided on the Investor section of the company's website. Fourth quarter revenue came in at $28.4 million, an increase of 44% from the $19.7 million we recognized during the same period in 2022.”
